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Results LU-102 reduced phosphorylation of IκB, in con-
trast to bortezomib and carfilzomib, and was a superior 
inhibitor of NF-κB activation in MM cells. This translated 
into highly synergistic cytotoxicity between LU-102 and 
ibrutinib, which was able to overcome BTZ resistance and 
CFZ resistance. By contrast, BTZ lacked consistent syner-
gistic cytotoxicity with ibrutinib.
Conclusion Ibrutinib is highly synergistic with 
β2-selective proteasome inhibition against MM and MCL 
in vitro. Novel β2-selective proteasome inhibitors may be 
exploited to overcome bortezomib/carfilzomib resistance 
and boost the activity of BTK inhibitors against B-cell-
derived malignancies.
Keywords Protease inhibitors · Myeloma therapy · 
Signal transduction · Drug resistance
Introduction
Treatment with proteasome inhibitors (PI) has become a 
backbone of therapy for multiple myeloma (MM) [1] and 
mantle cell lymphoma (MCL). This has established the 
proteasome as a molecular target and the manipulation of 
protein homeostasis as a therapeutic principle in cancer. 
However, bortezomib (BTZ), the first in class approved 
PI, is lacking significant single-agent activity in other 
B-cell-derived malignancies, so that several combination 
treatments are under clinical investigation [2]. In addi-
tion, resistance to BTZ almost inevitably occurs in MM 
and MCL patients during the course of the disease [1], 
underscoring the need to improve the activity of PI-based 
treatments.
The proteasome is a multicatalytic multiprotein protease 
complex responsible for the majority of protein destruction 
Abstract 
Purpose Proteasome-inhibiting drugs (PI) are gaining 
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ries three proteolytically active subunits (β1, β2, β5). All 
established PI (bortezomib and carfilzomib), as well as 
experimental drugs in the field (dalanzomib, oprozomib, 
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nit. It is unknown whether β2-selective proteasome inhi-
bition can also be exploited toward anticancer treatment. 
Combining PI with the pan B-cell-directed Bruton tyrosine 
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improved treatment of multiple myeloma (MM) and B-cell 
lymphomas. However, bortezomib induces phosphorylation 
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in eukaryotic cells [3]. Its proteolytic activity is mediated 
by three distinct active sites in the β1, β2, and β5 subunits 
that hydrolyze substrates with distinct substrate specifici-
ties (caspase-like, trypsin-like, and chymotrypsin-like). 
BTZ is a peptide-based, reversible inhibitor of the β5-type, 
and to a lesser extent the β1-type proteasome subunits, that 
was developed based on the finding that the β5 active site 
mediates the rate-limiting activity for proteasomal prote-
olysis [1]. Several second-generation, peptide-based, irre-
versible PI are in clinical development, including the FDA-
approved carfilzomib (CFZ), as well as ixazomib [4] and 
oprozomib [5], which all by design target the β5 protea-
some activity. The clinical activity of CFZ in BTZ-refrac-
tory MM is low and in the 20 % range [6].
Continuing progress in resolving the three-dimensional 
structure of the proteasome in complex with PI has facili-
tated the development of PI that selectively target the non-
β5 proteasome subunits, i.e., β2, β1 and the immuno-pro-
teasome. The β2 proteasome activity has been identified as 
critical factor that modulates the cytotoxicity of β5-targeted 
proteasome inhibitors [7–9], corresponding with the find-
ing that β2 proteasome activity is upregulated in BTZ-
refractory cells [10]. We have recently developed LU-102, 
the first irreversible, cell-permeable, β2-selective PI as 
a chemical lead for preclinical development [8], which is 
currently being tested in combination with the approved PI 
to overcome PI resistance in preclinical models. The poten-
tial of LU-102 for therapeutic use in combination with non-
PI anticancer agents remains to be defined.
B-cell-derived malignancies represent a natural target 
population for the development of PI-based combination 
therapies, such as CLL and mantle cell lymphoma [11, 12]. 
In addition, PI-refractory myeloma in vivo accumulates 
features of immature B cells [13], also implementing the 
use of pan B-cell-directed targeted agents against advanced 
MM. Hence, combining proteasome inhibitor therapy with 
a broadly active B-cell-targeting drug is a promising con-
cept to further exploit the cytotoxic anticancer activity of 
PI, in particular in MCL, CLL, and BTZ-refractory MM.
The Bruton tyrosin kinase (BTK) is a non-receptor tyros-
ine kinase expressed throughout the entire B-cell differen-
tiation [14], which plays a key role in B-cell development 
and function [15]. BTK signals through phosphorylation of 
PLC-γ, leading to phosphorylation of IκB and activation of 
the NF-κB signaling pathway, and also induces MAPK and 
AKT signaling. MAPK, STAT3, and in particular NF-κB, 
are critical signaling pathways for MM cell survival [16]. 
Ibrutinib is approved as first in class BTK inhibitor in 
MCL, chronic lymphatic leukemia, and Waldenström’s 
disease, and has shown clinical activity in MM and other 
B-cell-derived neoplasms. Combining ibrutinib with PI is 
currently explored using BTZ or CFZ, respectively, in MM 
and MCL.
The major signaling pathway of BTK as well as strong 
downstream signaling effects of BTZ converge in the canoni-
cal NF-κB pathway [17]: IκB is phosphorylated downstream 
of active BTK, generating p-IκB which is a target for ubiq-
uitination and proteasomal disposal, liberating the trans-
activating activity of NF-κB. Hence, the cytotoxic activity 
of ibrutinib is mediated via a decrease in p-IκB, leading to 
decreased NF-κB activity. By contrast, BTZ has been shown 
to increase p-IκB and induce NF-κB activity in MM cells 
[18]. This implies that combination therapies between BTZ 
and BTK inhibitors may have opposing effects on NF-κB 
signaling, which would be expected to limit their activ-
ity. However, also negative regulation of the NF-kB path-
ways by BTZ and induction of IkBα degradation have been 
shown [19–21]. The mechanism of the stabilization of p-IκB 
and NF-κB activity by BTZ in MM is poorly understood, 
but may involve off-target effects of BTZ, which is known 
to inhibit also lysosomal serine proteases such as cathepsin 
G and potentially other proteases [22]. Novel irreversible 
PI such as CFZ and LU-102 are more selective for the pro-
teasome and lack such off-target activity, so that they may 
be more suitable combination partners for ibrutinib to treat 
MM. The aim of the current study was to compare ibrutinib 
in combination with BTZ to combinations of ibrutinib with 
either CFZ or LU-102 with respect to the resulting effects 
on BTK signaling and cytotoxicity in MM cells, including 
BTZ-resistant myeloma. This aims at providing a preclinical 
rationale to select either BTZ or CFZ as combination partner 
for ibrutinib in MM clinical trials, and in addition shall allow 
to further explore a potential use of β2-selective proteasome 
inhibitors as combination partners in targeted therapies, in 
particular in the MM field.
Methods and materials
Cells and inhibitors
Human myeloma cell lines RPMI 8226, LP-1, AMO-1, 
U-266, MM.1S, MM.1R, human mantle cell lymphoma cell 
lines Granta-519 and Jeko-1, and the acute myeloid leu-
kemia cell line THP-1 were obtained from ATCC, human 
myeloma cell lines INA-6, JK-6, L363 from M. Gramatzki, 
Kiel, and were maintained in FCS-supplemented RPMI 
1640 medium with gentamycin. INA-6 is IL-6 dependent 
which was used at 500 U/ml. AMO-BTZ/CFZ cells were 
adapted to proteasome inhibitor-containing culture con-
ditions from the AMO-1 parental line as described [10]. 
The proteasome inhibitors bortezomib, carfilzomib, and 
LU-102 [8] were synthesized at the Leiden Institute of 
Chemistry, and ibrutinib was obtained from Pharmacyclics. 
The activity-based ibrutinib probe was synthesized and 
used as described recently [27].
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MTT assay, Western blot, Western blot quantification, 
antibodies
CellTiter 96® AQueous One Solution cell proliferation assay 
(Promega) was used to determine cell viability in MTT 
assays. Mean values from quadruplicate samples of one rep-
resentative experiment representing at least three independ-
ent experiments are presented. SDS-PAGE and Western blot 
was performed as described [10]. Western blots were quanti-
fied using Bio 1D software (Vilber Lourmat); Fluorescence 
signals of DMSO-treated cells were considered baseline 
levels. Anti-BTK (Tyr223), anti-p-BTK (pTyr223), anti-
p-65, and anti-cleaved caspase 3, 7, 9, anti-STAT3, and anti-
p-STAT3 antibodies were purchased from Cell Signalling 
Technology (Boston, USA), anti-IκBα and anti-p-IκBα from 
Becton–Dickinson (Heidelberg, Germany), anti-cleaved 
PARP from Promega (Madison, USA), anti-GAPDH and 
anti-β-actin from Sigma (St. Louis, USA), and anti-poly-
ubiquitinated proteins from Viva Bioscience (Exeter, UK).
Determination of proteasome activity by active site 
labeling
The covalent, proteasome-specific affinity probe Bodipy 
TMR-Ahx3L3VS (MV-151) was synthesized and used 
as described [23]. Both the constitutive and the immune-
proteasome subunits were irreversibly labeled by MV151 
in intact cells and resolved after cell lysis by SDS-PAGE. 
Proteasome subunit-specific fluorescence signals were in-
gel measured with the Fusion FX7 (Vilber Lourmat) and 
quantified using Bio 1D software.
RNA extraction and real‑time PCR
RNA was extracted from 5 × 106 cells using phenol–
chloroform method. Reverse transcription was performed 
using the High-Capacity cDNA Reverse Transcription Kit 
with RNAse Inhibitor (Applied Biosystems). Real-time 
PCR primers for GAPDH and BTK were purchased from 
Qiagen. Relative quantitative real-time PCR used SYBR 
green technology (Roche) on cDNA generated from the 
reverse transcription of purified RNA. After preamplifica-
tion (95 °C for 10 min), the PCRs were amplified for 45 
cycles (95 °C for 10 s, 55 °C for 20 s and 72 °C for 20 s) on 
a LightCycler® 480 (Roche). Each mRNA expression was 
normalized against GAPDH mRNA expression using the 
standard curve method.
Patient cells
The primary myeloma cell samples were obtained 
after written informed consent and approval by the 
independent ethics review board, in accordance with 
ICH-GCP and local regulations. Malignant plasma cells 
were retrieved by bone marrow aspiration from patients 
with multiple myeloma progressing under bortezomib-
containing therapy (BTZ-resistant) or responding to bort-
ezomib (BTZ-sensitive), based on IMWG criteria. The 
purity of the cell sample was >80 % myeloma cells after 
Ficoll separation, as assessed by morphology. Cells were 
cultured in FCS-supplemented RPMI 1640 medium with 
gentamycin.
Statistical analysis
Unless stated otherwise, one representative experiment 
out of at least three independent experiments is shown; 
for MTT assays, mean values from quadruplicate samples 
are represented. Error bars indicate the standard deviation 
between the individual experiments or samples. Synergism 
between ibrutinib and the different proteasome inhibitors 
was calculated using MTT assays in conjunction with the 
combination index described by Chou et al. [24]. A combi-
nation Index <0.8 indicates synergism, >1 indicates antago-
nism. The statistical significance was calculated using stu-
dent’s t test.
Results
BTK expression and ibrutinib‑mediated cytotoxicity 
in MM cell lines
We analyzed a panel of MM and mantle cell lymphoma 
(MCL) cell lines with respect to protein and mRNA expres-
sion of BTK and p-BTK, respectively, and correlated the 
results with the cytotoxic effect of ibrutinib in vitro. Con-
sistent with published data [25, 26], we found sizable BTK 
protein expression in the MM cell lines INA-6, LP-1, and 
to a lesser extent in MM.1R cells, in contrast to the remain-
ing MM cell lines (AMO-1, AMO-BTZ, AMO-CFZ, JK-6, 
L363, MM.1S, RPMI 8226 and U-266; Fig. 1a). The 
mRNA transcription levels for BTK only poorly correlated 
with the respective protein expression, also in agreement 
with earlier studies [25]. Interestingly, the sensitivity of 
MM and MCL cell lines for ibrutinib-induced cytotoxic-
ity also only poorly reflected the protein expression levels 
of p-BTK in the individual cell lines (Fig. 1b). Because 
the majority of primary human MM cell samples express 
p-BTK protein and are sensitive to cytotoxic treatment with 
ibrutinib 10 μM in vitro [26], we selected INA-6 MM cells 
as a suitable model system to study the effects of ibrutinib 
in combination with proteasome inhibitors on MM cell 
lines in vitro.
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Fig. 1  BTK expression and ibrutinib-mediated cytotoxicity in MM cell 
lines. a Upper panel MM cell lines (AMO-1, AMO-BTZ, AMO-CFZ, 
INA-6, JK-6, L363, LP-1 MM.1R, MM.1S, RPMI 8226 and U-266), 
MCL cell lines (Granta-519 and Jeko-1), and AML cell line (THP-1) 
were analyzed with respect to protein expression of BTK. After cell 
lysis, equal amounts of protein were resolved by SDS-PAGE, and 
Western blots against BTK and activated BTK (p-BTK) were per-
formed. Ponceau S staining of the same PVDF membrane that was 
used for the blots confirms equal protein contents between lanes. Lower 
panel The same cell lines were analyzed for BTK mRNA expression 
by real-time PCR. Results are expressed in relation to mRNA for 
GAPDH. b MM cell lines (MM.1R, LP-1, INA-6, RPMI 8226, AMO-
1, AMO-BTZ and AMO-CFZ) and MCL cell lines (Granta-519 and 
Jeko-1) were incubated with ibrutinib at indicated concentrations for 
48 h and cell viability was assessed by MTT proliferation assay
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Ibrutinib reduces p‑IκB levels and lacks a direct  
effect on proteasome activity in MM cell lines
We next assessed the molecular effects of ibrutinib on the 
p-BTK/p-IκB signaling cascade as well as on the protea-
some activity in INA-6 cells. As expected, ibrutinib inhib-
ited the p-BTK expression in a dose-dependent manner 
already at nanomolar concentrations (Fig. 2a). Likewise, 
a dose-dependent reduction in p-IκB expression consist-
ent with the known effect of ibrutinib on BTK signaling 
was observed, starting at high nanomolar drug levels. As 
expected, ibrutinib had no direct effect on the activity of 
the proteasomal β1, β2, or β5 subunits, as visualized by 
the cell-permeable, pan-proteasome-selective, activity-
based probe MV151 that irreversibly targets the active 
constitutive and immuno-proteasome subunits in situ and 
allows their direct quantification by fluorescence detection 
(Fig. 2b).
The β2‑selective proteasome inhibitor LU‑102  
decreases p‑IκB expression, in contrast  
to bortezomib or carfilzomib
The cytotoxic activity of ibrutinib is transmitted via reduc-
tion in p-IκB levels, while in contrast BTZ has been shown 
to moderately increase p-IκB in MM cells [18], which 
would predict to limit the synergistic activity of both drugs. 
We therefore compared the effect of BTZ on p-IκB with that 
of CFZ, as well as the β2-selective peptide vinylsulfone-
type proteasome inhibitor LU-102 [8]. INA-6 MM cells 
were incubated with the respective proteasome inhibitors in 
a concentration range that included the IC50 for each inhibi-
tor, and their differential effects on proteasome activity, 
the accumulation of polyubiquitinated cellular protein, and 
p-IκB/IκB protein expression were visualized (Fig. 3). In 
BTZ-treated cells, we observed a concentration-dependent, 
β1-/β5-selective reduction in proteasome activity that was 
accompanied by a respective increase in polyubiquitinated 
protein. Also in agreement with published data, BTZ treat-
ment led to a slight decrease in IκB, while p-IκB expression 
increased (Fig. 3, upper panel), resulting in an increased 
p-IκB/IκB ratio. CFZ treatment did likewise reduce the β1/
β5 proteasome activity signal with a concomitant increase 
in polyubiquitinated protein, comparable to BTZ. CFZ 
treatment at higher concentrations (10 nM and higher) in 
addition resulted in a small, but reproducible reduction in β2 
activity, unlike BTZ. The ratio of p-IκB/IκB expression like-
wise increased under CFZ treatment (Fig. 3, middle panel). 
In contrast to both approved proteasome inhibitors, LU-102 
specifically targeted the β2-/2i-type proteasome activity, 
without affecting the activity signals for β1/β5 subunits 
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Fig. 2  Molecular effects of ibrutinib on the target proteins p-BTK/BTK, 
the downstream p-IκB/IκB activation and proteasome subunit activity. 
a Upper panel INA-6 cells were incubated with increasing ibrutinib 
concentrations (0–10 µM) for 4 h, and p-BTK and BTK proteins were 
assessed by Western blot. The bar graph illustrates the quantitative com-
parison of the fluorescence signals retrieved for p-BTK protein at the 
respective ibrutinib concentrations, relative to baseline (DMSO-treated). 
Lower panel INA-6 cells were incubated with increasing ibrutinib con-
centrations (0–10 µM) for 8 h, before IκB and activated IκB (p-IκB) 
proteins were determined by Western blot and quantified as described 
above. For a statistically significant quantitative difference from base-
line, *p < 0.05; **p < 0.01. b After incubation with increasing ibrutinib 
concentrations (0–10 µM), active proteasome subunits in INA-6 cells 
were affinity-labeled using the fluorescent, pan-proteasome reactive, 
cell-permeable probe MV-151 for 1 h. After resolution by SDS-PAGE, 
the fluorescence signals representing active proteasome β1, β2, β5 pol-
ypeptides and the respective immuno-proteasome species β1i, β2i, β5i 
were visualized using a fluorescent reader and quantitated. Conventional 
Western blotting against GAPDH demonstrates equal protein load of the 
samples. The bar graph above illustrates the quantitative comparison of 
the specific fluorescence signals detected for the proteasomal β1(i)/β5(i) 
and β2(i) activities, relative to DMSO-treated baseline
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(Fig. 3, lower panel). An increase in polyubiquitinated pro-
tein was not observed with LU-102 treatment, suggesting 
less effective quantitative reduction in protein degradation 
during β2-selective proteasome inhibition. Surprisingly, and 
in contrast to BTZ and CFZ, LU-102 treatment resulted in a 
concentration-dependent decrease in p-IκB levels, so that a 
significant decrease in the ratio of p-IκB/IκB expression was 
observed in INA-6 cells after LU-102 treatment. Thus, the 
β2-selective proteasome inhibitor LU-102 decreases cellular 
p-IκB levels and the p-IκB/IκB ratio and therefore may sup-
port the signaling cascade triggered by ibrutinib, in contrast 
to the β1/β5-selective proteasome inhibitors CFZ and BTZ 
that stabilize p-IκB levels and increase the p-IκB/IκB ratio. 
We speculated that LU-102 may result in superior synergis-
tic cytotoxic activity in combination with ibrutinib, com-
pared to BTZ or CFZ.
Ibrutinib in combination with LU‑102 shows superior 
synergistic cytotoxicity against MM cells
We next analyzed the effects of ibrutinib in combination 
with the different proteasome inhibitors on cytotoxicity 
and activity of the NF-κB pathway in INA-6 MM cells. 
The combination of ibrutinib with either BTZ or CFZ at 
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Fig. 3  Molecular effects of bortezomib, carfilzomib, and the 
β2-specific proteasome inhibitor LU-102 on proteasome subunit 
activities, the p-IκB/IκB ratio and polyubiquitinated protein. Left 
panels After incubation with increasing proteasome inhibitor concen-
trations (bortezomib, carfilzomib: 0–33.3 nM; LU-102: 0–10 µM), 
active proteasome subunits in INA-6 cells were affinity-labeled using 
the cell-permeable probe MV-151, and visualized as before. Right 
panels INA-6 cells were incubated with the respective proteasome 
inhibitors, as before, followed by assessment of p-IκB, IκB, and poly-
ubiquitinated proteins (poly-UB) by Western blots. One representa-
tive of two experiments performed
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sub-cytotoxic concentrations did not significantly affect 
cell viability, compared with ibrutinib alone (Fig. 4a, upper 
panel), and resulted in borderline synergistic cytotoxic 
activity with combination indices of 0.6 and 0.8, respec-
tively. By contrast, the combination of ibrutinib with sub-
effective LU-102 resulted in a highly synergistic cytotoxic 
effect on INA-6 cells with a combination index of 0.075. 
While myeloma cell viability after treatment with ibrutinib 
in combination with BTZ or CFZ was 46 and 42 %, respec-
tively, and thus in the same order of magnitude as after 
ibrutinib monotherapy, it was reduced to 7 % by combina-
tion treatment with LU-102. Consistent with this, as well as 
with the data described above, the combination of ibrutinib 
with LU-102 showed superior suppression of p-IκB, p-p65, 
and p-STAT3 protein expression, as well as induction of 
cleaved caspase 3, 7 and 9 and cleaved PARP, compared 
with ibrutinib in combination with either bortezomib or 
carfilzomib (Fig. 4a, lower panel). These findings demon-
strate that that LU-102 is a superior combination partner 
for ibrutinib, compared with CFZ or BTZ, to induce cyto-
toxicity in MM cells.
Ibrutinib in combination with LU‑102 shows synergistic 
cytotoxicity against proteasome inhibitor‑resistant MM 
cells
We next explored to what extent the combination of 
LU-102 and ibrutinib may likewise be cytotoxic against 
MM cells resistant against BTZ or CFZ. To serve as a 
model for proteasome inhibitor resistance, AMO-1 MM 
cell lines were adapted to grow in the presence of the two 
approved proteasome inhibitors as published before for 
bortezomib, yielding AMO-1 cell populations with differ-
ential sensitivity for BTZ or CFZ (AMO-1, AMO-BTZ, 
AMO-CFZ, supplemental material). Interestingly, CFZ-
adapted cells (AMO-CFZ) were still sensitive to BTZ at 
high concentrations, while BTZ-adapted cells (AMO-BTZ) 
lacked CFZ sensitivity up to 100 nM, suggesting different 
mechanisms of proteasome inhibitor resistance between 
these two cell populations or the two drugs. When these 
cell populations were exposed to ibrutinib or LU-102 at 
sub-effective concentrations or to the combination of both 
drugs, respectively, we observed strong synergistic cyto-
toxic activity of this combination against the AMO-1 wild-
type cells as well as the CFZ- or BTZ-adapted populations 
(Fig. 4b, upper panel and supplemental material). To fur-
ther support that MM cells that are resistant to the approved 
proteasome inhibitors are sensitive to the combination of 
LU-102 and ibrutinib, we obtained primary MM cells from 
three patients with clinically bortezomib-resistant MM and 
exposed them to bortezomib 10 nM or LU-102 1 μM, ibru-
tinib 10 μM, or the combination of the latter two in vitro 
(Fig. 4b, lower panel). Cell viability was largely unaffected 
by either of the drugs alone, while the combination between 
LU-102 and IBR again yielded a highly synergistic cyto-
toxic effect between both compounds (CI 0.015).
BTZ does not induce consistent, synergistic cytotoxicity 
with ibrutinib in MM and MCL cell lines, in contrast 
to CFZ and LU‑102
We finally challenged a panel of MM cell lines (LP-1, 
MM.1R, RPMI 8226) and MCL cell lines (Granta-519 and 
Jeko-1), which differed in their degree of BTK expression 
and ibrutinib sensitivity, with sub-effective concentrations of 
BTZ, CFZ, or LU-102, in the presence or absence of ibru-
tinib (Fig. 5), and calculated the respective combination 
indices for synergy (CI) after assessment of cytotoxicity by 
MTT assay. We observed that, in particular, BTZ was a poor 
combination partner with ibrutinib that did even result in an 
antagonistic CI of >1 in 4/5 of the cell lines tested (Table 1, 
median CI 4.9, range 0.3–30.3). By contrast, synergistic 
cytotoxicity with ibrutinib was seen in 5/5 cell lines with 
CFZ (median CI 0.12, range 0.03–0.22) and in 5/5 cell lines 
with LU-102 as combination partner (median 0.02, range 
0.001–0.14). Our results therefore demonstrate that BTZ is a 
relatively poor combination partner to increase the cytotoxic 
effect of ibrutinib against MM or MCL cells, while CFZ, and 
in particular LU-102, show consistently strong synergistic 
cytotoxicity with ibrutinib. LU-102 appears to have an even 
stronger synergistic potential in combination with ibrutinib 
than CFZ, based on the CI values calculated.
Visualization of a non‑BTK off‑target protein 
of ibrutinib
Interestingly, the synergistic cytotoxic activity between 
ibrutinib and LU-102 was observed not only in MM/MCL 
cells lines with high BTK expression, but to almost the 
same extent also in cells with low/absent detectable BTK 
protein expression. This suggested that ibrutinib may have 
additional, as yet unknown cellular targets.
To identify putative additional cellular targets for ibruti-
nib, we synthesized a cell-permeable derivative of ibrutinib 
with an incorporated fluorescent label that can be used to tag 
and visualize ibrutinib-reactive proteins in intact cells after 
cell lysis and SDS-PAGE due to the covalent target bind-
ing of the active compound [27]. Intact cells were incubated 
with this activity-based ibrutinib probe (ibrutinib-ABP) and 
subjected to subsequent cell lysis, SDS-PAGE, and fluores-
cence in-gel detection (Fig. 6). To verify the ibrutinib-sensi-
tive nature of binding of the probe and the specificity of the 
labeled polypeptides, control cells were pre-incubated either 
with ibrutinib or with an inactive version of the probe that 
lacked the reactive group for covalent target binding (mock). 
Active BTK was identified as prominently labeled protein 
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species in BTK-positive cells, based on its expected MW of 
78 kD, and the nature of labeling that could be blocked by 
preincubation with ibrutinib but could only be partly com-
peted by the non-covalent mock competitor of the affin-
ity label. Also as expected, and consistent with our results 
from Western blots, INA-6 cells showed a robust BTK sig-
nal, while this signal was considerably lower in RPMI 8226, 
AMO-1, AMO-BTZ, and Jeko-1 cells, as well as in non-
B-cell-type samples. Treatment of INA-6 cells with 1 mM 
ibrutinib entirely abolished the BTK activity signal in the 
absence of significant cytotoxicity (see Fig. 1b, indicating 
that BTK-expressing MM cells may not undergo significant 
cytotoxicity upon BTK inhibition alone.
We observed a second protein species of lower labeling 
intensity at 64 KD (upper band of the doublet polypeptides 
at 61 and 64 kD), which was decorated by the probe in spe-
cific way, comparable to BTK labeling, and whose labeling 
was antagonized by ibrutinib or, to a lesser extent, the non-
covalent label with selectivity similar to that of BTK. This 
protein was detectable with low, but reproducible signal 
intensity in all B-cell lines used, irrespective of their BTK 
expression, and in particular in AMO-1 and AMO-BTZ 
cells. This labeled 64-kD polypeptide was absent from 
BT-549 breast cancer cells. We hypothesize that this pro-
tein is likely an as yet unidentified target kinase of ibrutinib 
distinct from BTK that may be the relevant for the effects 
of ibrutinib on BTK-negative MM and MCL cells alone or 
in combination with proteasome inhibition.
Discussion
Our data demonstrate that LU-102 has superior synergis-
tic cytotoxic activity with ibrutinib on MM and MCL cells, 
compared to BTZ, most likely due to its synergistic inhibi-
tion of p-IκB and the canonical NF-κB pathway, and that 
the combination of ibrutinib and LU-102 can overcome 
BTZ and CFZ resistance in vitro. We furthermore provide a 
first example that PI that target different proteasome active 
subunits can differentially affect cancer cell signaling or 
the activity of targeted cancer therapies: β2-selective pro-
teasome inhibition did not result in gross quantitative inhi-
bition of proteolytic degradation, as seen by the absence of 
accumulating polyubiquitinated protein after LU-102 treat-
ment, but reduced p-IκB levels and was more effective in 
mediating cytotoxicity in combination with ibrutinib, com-
pared with bortezomib that is exclusively inhibiting β5/β1 
activity (Fig. 3). This has implications for the development 
of future proteasome-inhibiting therapies and drugs, where 
to date little attention is being paid to the different patterns 
Fig. 4  Cytotoxic effect of ibrutinib in combination with bortezomib, 
carfilzomib, and LU-102. a Upper panel INA-6 cells were incubated 
with bortezomib (BTZ) 3.3 nM, carfilzomib (CFZ) 3.3 nM, LU-102 
(LU) 3.3 µM or ibrutinib (IBR) 10 µM or a combination of ibrutinib 
with one of the proteasome inhibitors, and cell viability was assessed. 
(CI combination index). Statistically significant differences were 
expressed as *p < 0.05, **p < 0.01, and ***p < 0.005. Lower panel, 
left After incubation of INA-6 cells with DMSO control (0), or a 
combination of ibrutinib (i) 10 µM and either bortezomib (b) 10 nM, 
carfilzomib (c) 10 nM or LU-102 (LU) 3.3 µM, Western blots against 
p-IκB, p-p65, p-STAT3, STAT3, cleaved caspases 3, 7, 9 and cleaved 
poly ADP ribose polymerase (PARP) proteins were performed and 
quantified as before. Right quantification of the Western blot signals 
retrieved for p-p65 and p-IκB. Bar graphs represent amounts of the 
detected p-p65 and p-IkB species under the different treatments, 
relative to baseline values with DMSO treatment. Asterisk indicates 
a statistically significant quantitative difference between BTZ- and 
LU-102-treated samples p < 0.05. b Upper panel AMO-1, AMO-
BTZ, and AMO-CFZ cells were incubated with LU-102 and ibruti-
nib (AMO-1: LU-102 3.3 µM, ibrutinib 10 µM; AMO-BTZ: LU-102 
10 µM and ibrutinib 10 µM; AMO-CFZ: LU-102 3.3 µM and ibruti-
nib 33.3 µM) or with the combination of both for 48 h and cell viabil-
ity was assessed by MTT assay. Lower panel Primary MM cells from 
four myeloma patients with bortezomib-resistant (3 patients, BTZ-
res.) or bortezomib-sensitive (1 patient, BTZ-sensitive) MM were 
exposed to bortezomib (BTZ) 10 nM or LU-102 (LU) 1 µM, ibrutinib 
(IBR) 10 µM, or the combination of the latter two for 48 h, and cell 
viability was assessed
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test. Results are expressed relative to cells treated with DMSO (0)
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of inhibition of the total of six active subunits of the consti-
tutive and immuno-proteasome.
The potential use of proteasome inhibition in com-
bination with the BTK inhibitor ibrutinib (IBR) in MM 
has already entered clinical trials (ClinicalTrials.gov, 
NCT01962792), although we currently lack understand-
ing of the molecular interactions between both targeted 
pathways. Moreover, proteasome inhibitors with different 
active groups and molecular targets continue to be devel-
oped, while we have little rationale that guides our choice 
of proteasome inhibitor selected for such a strategy. Based 
on published information, we predicted that bortezomib 
may partially counteract the molecular mechanism of 
action of ibrutinib in MM cells, because it induces NF-κB 
activation in MM cells [18], while ibrutinib acts, at least 
partially, through NF-κB inhibition in MM [26].
The molecular basis for the different effects of bort-
ezomib and carfilzomib, on the one hand, and LU-102 
on the other hand, on the p-IκB/IκB balance remains to 
be explained. Consistent with our data from INA-6 cells, 
Hideshima demonstrated in RPMI 8226 myeloma cells, 
that not only bortezomib, but also the β5-directed, reversi-
ble peptide aldehyde proteasome inhibitor MG-132 and the 
irreversible pan-proteasome inhibitor lactacystin resulted 
in accumulation of p-IκB and decreased IκB levels which 
are predicted to counteract the molecular activity of ibru-
tinib. Thus, neither the nature of the chemical warhead of 
the proteasome inhibitor (peptide aldehyde, epoxyketone, 
β-lactone, and petide boronate), nor its reversibility of tar-
get binding seems to be of importance for these differen-
tial effects. In contrast to the proteasome inhibitors men-
tioned above, LU-102 does not inhibit or co-inhibit the 
rate-limiting β5 subunit of the proteasome, but provides 
β2-selective proteasome inhibition. This β2-selective pro-
teasome inhibition results in a less effective quantitative 
inhibition of proteasomal proteolysis, as demonstrated by 
the absence of accumulated polyubiquitinated protein in 
our results. Because p-IκB is a known proteasome substrate 
that undergoes proteasomal degradation, we speculate that 
the increase in p-IκB after carfilzomib/bortezomib treat-
ment may be attributed to the quantitative inhibition of pro-
tein destruction by these β5-inhibiting agents, in contrast to 
LU-102.
Recent data show that β5-directed proteasome inhibi-
tion can result in IκBα degradation via the lysosomal path-
way that is induced in an IκB-kinase-independent man-
ner [28]. Our results are consistent with the model that 
p-IκB-independent lysosomal degradation of IκBα occurs 
in MM cells exposed to β5-targeted proteasome inhibi-
tors like carfilzomib or bortezomib. By contrast, because 
the β2-directed inhibitor LU-102 does not quantitatively 
affect the global balance between protein biosynthesis and 
destruction, LU-102 may not activate the lysosomal system 
to bypass the obstructed proteasomal proteolysis. Indeed, 
it has been demonstrated that blocking autophagy prevents 
bortezomib-induced NF-κB activation by reducing IκBα 
degradation in lymphoma cells [29].
Ibrutinib can increase the cytotoxic effect of bortezomib 
on myeloma patient cells in vitro [30], consistent with our 
results. However, we lack information about the nature of 
this effect, whether it is synergistic or may even in part be 
antagonistic, i.e., less than additive. The latter could still 
result in an increased cytotoxicity, compared with one drug 
alone, but would argue against further clinical development 
of both drugs in combination. In our results, bortezomib 
was not synergistic with ibrutinib in myeloma or mantle 
cell lymphoma cell lines (CI median 4.9), while carfilzomib 
showed a consistent synergism (CI median 0.12), in agree-
ment with recent data from combinatorial drug screening 
in mantle cell lymphoma [31]. The most robust synergistic 
cytotoxicity, however, was induced by LU-102 (CI median 
0.028, range 0.001–0.14), consistent with our analy-
sis of p-IκB/IκB signaling, in multiple cell lines of MM 
and MCL as well as in bortezomib-resistant primary MM 
Table 1  Combination Index 
(CI) for cytotoxic activity, MTT 
test
Combination indices (CI) for synergistic cytotoxic activity in vitro (Fig. 5) between ibrutinib (IBR) in com-
bination with either bortezomib (BTZ), carfilzomib (CFZ), or LU-102 were calculated from MTT tests 
as described in materials and methods using the MCL and MM cell lines indicated. A CI < 0.8 indicates 
synergism, a CI > 1 antagonism. The different degrees of expression of BTK protein are indicated for the 
respective cell lines, as assessed by Western blot (– for no detectable BTK protein, +, ++, +++ for little, 
moderate and strong BTK protein expression, respectively)
BTK protein IBR + BTZ IBR + CFZ IBR + LU-102
Granta-519 (MCL) ++ 5.109 0.099 0.036
Jeko-1 (MCL) – 4.994 0.144 0.015
LP-1 (MM) ++ 30.333 0.031 0.001
MM.1R (MM) + 4.319 0.220 0.145
RPMI 8226 (MM) – 0.300 0.032 0.023
INA-6 (MM) +++ 0.83 0.63 0.075
Median 4.9 0.12 0.02
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cells. Interestingly, this synergistic cytotoxic activity can be 
observed not only in MM/MCL cells lines with high BTK 
expression, but to almost the same extent also in cells with 
low/absent detectable BTK protein expression. This sug-
gested that ibrutinib may have additional, as yet unknown 
cellular targets that may be involved in mediating this effect.
At present, it is unclear how inhibition of the β2 protea-
some activity fosters synergistic cytotoxicity with ibruti-
nib. In contrast to bortezomib, also carfilzomib has some 
β2-inhibiting activity, which may provide the mechanistic 
link for the higher degree of synergy of carfilzomib or 
LU-102 with ibrutinib, compared with bortezomib. The pro-
teasome is involved in controlling the intracellular levels of 
not only structural, but also most regulatory cellular proteins 
involved in cell cycling, proliferation, and differentiation. 
The different substrate specificities of the β5 versus β2 are 
consistent with the hypothesis that β5 inhibition versus β2 
inhibition may differentially affect the turnover of some 
key regulatory proteins. A key role of individual “unlock-
ing” proteases that can control the proteolytic destruction 
Fig. 6  Visualization of 
ibrutinib-targeted proteins using 
a fluorescent synthetic ibrutinib-
analog as activity-based 
covalent problem. a DLBCL 
type cell lines (HBL1, OciLy3, 
SU-DHL4), MM (INA-6, RPMI 
8226) and the HaCat melanoma 
cell line were incubated with 
either DMSO, ibrutinib (IBR), 
or a mock version of ibrutinib-
ABP lacking the active warhead 
(mock, 1 µM each), before 
cells were exposed to activity-
based covalent affinity labeling 
(1 μM) by incubation with 
ibrutinib-ABP. After cell lysis, 
cellular protein was dissolved 
by SDS-PAGE and fluores-
cent signals visualized using 
a fluorescence reader. Western 
blotting for β-actin served as 
loading control from the same 
samples. b BTK-expressing 
(Granta-519, HL-60) cell lines 
and cell lines without BTK 
expression (Jeko-1, AMO-1, 
AMO-BTZ, as well as the 
breast cancer cell line BT-549) 
were incubated with DMSO 
(0), ibrutinib (IBR), or a mock 
treated as before, and ibrutinib-
reactive protein species were 
visualized as before. Western 
blotting for β-actin served as 
loading control
Granta-519           HL-60                  Jeko-1
IBR     0   mock IBR    0     mock IBR    0     mock
β-actin
IBR     0     mock IBR     0    mock IBR     0     mock
AMO-1              AMO-BTZ         BT-549
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of individual substrate proteins in a multiprotease proteo-
lytic pathway has been demonstrated for lysosomal antigen 
processing [32]. The β2 proteasome subunit may likewise 
control the degradation of a regulatory key protein that is 
involved in mediating ibrutinib-induced cell death.
Overcoming proteasome inhibitor resistance is a major 
problem for MM therapy. Recent data from thorough 
analysis of in vitro models and patient material demon-
strate that proteasome inhibitor resistance is most likely 
a selection process of myeloma cells under the selective 
pressure of proteasome inhibitors. During this process, 
myeloma cells with preplasmoblast-like features and low 
levels of XBP-1, the major regulator of the unfolded pro-
tein response that at the same time determines plasmo-
blast differentiation and proteasome inhibitor sensitivity, 
accumulate [13]. Combining proteasome inhibition with 
a targeted therapy directed against the entire B-cell line-
age, including immature cells, such as BTK inhibition, is 
a rational strategy to simultaneously treat both, the pro-
teasome inhibitor-sensitive mature myeloma cells and the 
proteasome inhibitor-resistant immature cell populations. 
We here investigate this concept in an in vitro model that 
reflects these fundamental principles: The bortezomib-
resistant and carfilzomib-resistant AMO-1 cells (AMO-
BTZ, AMO-CFZ) used here have been generated under 
the selective pressure of the proteasome-inhibiting drugs 
and show significantly decreased XBP-1 levels, compared 
with the AMO-1 parental line, but at the same time lack 
mutations in the active sites of the proteasome ([10] and 
M. Kraus, unpublished results), so that they in this respect 
closely mimic the situation encountered in vivo. Compared 
to their parental cells, AMO-BTZ in particular expresses 
increased activity of the β2 proteasome subunit that is not 
targeted by bortezomib, a feature that might also contrib-
ute to BTZ resistance [10]. Our results demonstrate that 
combination treatment with the β2 inhibitor LU-102 and 
ibrutinib overcomes the features of proteasome inhibitor 
resistance and has significant synergistic cytotoxic activity 
against proteasome inhibitor-adapted myeloma cells, com-
parable to the proteasome inhibitor-sensitive parental cell 
line. Importantly, this feature was similarly observed when 
primary multiple myeloma cells from a patient with bort-
ezomib-refractory disease were challenged with LU-102 
in combination with ibrutinib, while both agents alone had 
no cytotoxic effect. It has been previously shown that the 
co-administration of ibrutinib with bortezomib increased 
cytotoxicity in bortezomib-resistant MCL and DLBCL 
cells; however, the NF-kB inducing effet of bortezomib 
has only been observed in MM and may be linked to the 
highly developed protein biosynthesis machinery of MM 
cells [18]. Murray et al. [33] very recently demonstrated 
that BTK activity was enhanced in bortezomib-resistant 
MM, and that co-treatment of MM cells with ibrutinib or a 
p65-targeted lentiviral construct and bortezomib can partly 
restore bortezomib sensitivity, highlighting the crucial role 
of NF-kB activity in bortezomib-resistant MM. Our results 
support this concept and furthermore show that ibrutinib 
in combination with the β2-selective PI LU-102 results in 
superior inhibition of NF-kB activation and significantly 
improved synergistic cytotoxicity, compared with bort-
ezomib. The combination of ibrutinib and β2-selective pro-
teasome inhibition may therefore represent a rational strat-
egy to overcome proteasome inhibitor resistance of MM. 
At the same time, our results suggest therapeutic potential 
also for proteasome inhibitors that do not target the rate-
limiting β5 proteasome subunit.
Although our data strongly support synergistic cyto-
toxicity between LU-102 and ibrutinib on myeloma cells, 
involving at least partly the NFkB pathway, BTK is likely 
not the only relevant target of ibrutinib in this setting. In 
our results, as well as other studies investigating the cyto-
toxic activity of ibrutinib on myeloma cells in vitro [26, 
30], only very high concentrations of ibrutinib (10 μM) 
triggered a direct cytotoxic effect on myeloma cells, and 
BTK-negative cells were sensitive for synergistic cyto-
toxicity with ibrutinib and LU-102, suggesting alternative 
targets that are likewise inhibited by ibrutinib in myeloma 
cells. Indeed, ibrutinib (formerly PCI-32765) is known to 
target >20 different kinases at IC50 values below 1 μM 
[34]. Importantly, the cytotoxic activity of ibrutinib in 
myeloma has meanwhile been confirmed in a clinical 
phase II trial, but also clinically the ibrutinib dose required 
for maximum clinical mono-activity against myeloma was 
twice the standard dose used in CLL (840 mg daily, Vij R, 
et al. ASH 2014. Abstract 31), also suggesting alternative 
targets with slightly lower affinity involved in ibrutinib 
activity in myeloma. Using a fluorescence-labeled deriva-
tive of ibrutinib, we here demonstrate that indeed ibrutinib 
a non-cytotoxic concentration of 1 μM not only eliminates 
BTK activity in MM cells, but specifically targets also 
an unidentified 64-kD polypeptide that is present also in 
bortezomib-resistant myeloma cells that lacked detect-
able BTK expression but were sensitive to the combina-
tion ibrutinib + LU-102. We are currently on the way to 
design a biotin derivative of this ibrutinib probe to be able 
to isolate and identify the 64-kDa protein species and to 
prove its functional importance. At current stage, our data 
suggest that ibrutinib has additional, non-BTK targets in 
myeloma cells, which may be of functional relevance for 
the mechanism of action of ibrutinib against myeloma.
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